Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Protagonist Therapeutics
Biotech
Protagonist hands rusfertide rights to Takeda for $475M payday
After mulling its options, Protagonist decided to pocket $475 million rather than split the U.S. profits for a hematology asset.
James Waldron
Apr 28, 2026 11:05am
Protagonist prefers $400M from Takeda over rusfertide US profits
Feb 26, 2026 10:00am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
J&J eyes takeover of immunology partner Protagonist: WSJ
Oct 10, 2025 2:30pm
J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial
Sep 17, 2025 9:45am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
